Cover Image
市場調查報告書

茲卡病毒疫苗的全球市場:未來方案分析 (急速成長/中成長/低成長方案),市場機會分析,產業預測

Zika Virus Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2022

出版商 Allied Market Research 商品編碼 436155
出版日期 內容資訊 英文 97 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
茲卡病毒疫苗的全球市場:未來方案分析 (急速成長/中成長/低成長方案),市場機會分析,產業預測 Zika Virus Vaccines Market by Forecast Scenario Analysis (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2022
出版日期: 2017年01月01日 內容資訊: 英文 97 Pages
簡介

本報告提供全球茲卡病毒疫苗市場未來展望相關分析,茲卡病毒概要和感染情形,疫苗開發的動向與未來可能性 (方案分析),今後的市場趨勢的考察,各地區、各國市場趨勢預測 (今後7年份),主要企業簡介等的相關調查。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 主要的投資財源
  • 茲卡病毒:概要
    • 茲卡病毒的感染、傳染形態
      • 母子感染
      • 性交
      • 輸血
      • 院內感染
    • 感染的症狀
    • 茲卡病毒的防止、管理
      • 媒介生物驅除選擇
        • 對目標居民的散佈
        • 對指定區域的散佈
      • 個人用防護手段
    • 患病人數、發病數量
    • 茲卡病毒的診斷、治療
      • 三重即時RT-PCR法檢驗
      • MAC-ELISA法檢驗
  • 由於FDA (美國食品藥物管理局) 的疫苗法規
    • 美國國內的疫苗執照交付情形
    • 優先審查憑證制度
    • 在美國國內認證的黃病毒疫苗
  • 臨床實驗
  • 全球主要疫苗產品的價格趨勢
  • 市場機會
    • 茲卡熱相關的先天性缺損的防止、治療的醫療解決方案:需求急速擴大
    • 茲卡熱的盛行率的上升

第4章 茲卡病毒疫苗的未來方案分析

  • 概要
    • 市場規模與其預測
      • 急速成長方案
      • 中成長方案
      • 低成長方案

第5章 茲卡病毒疫苗的潛在市場分析:各地區

  • 介紹
  • 北美
    • 市場規模與其預測
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲 (LAMEA)

第6章 茲卡病毒疫苗的潛在市場分析:各國

  • 巴西
    • 市場規模與其預測
  • 墨西哥
  • 菲律賓
  • 越南
  • 泰國
  • 其他國家 (RoW)

第7章 企業簡介

  • BHARAT BIOTECH INTERNATIONAL LTD
    • 企業概要
    • 企業的最新趨勢
    • 事業領域、業績
    • 產品平台
    • 研究資金財源
    • 主要策略的發展情形
  • GENEONE LIFE SCIENCE, INC.
  • GLAXOSMITHKLINE PLC
  • HAWAII BIOTECH INC
  • IMMUNOVACCINE INC.
  • INOVIO PHARMACEUTICALS, INC
  • NEWLINK GENETICS CORPORATION
  • SANOFI S.A.
  • 武田藥品工業

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: LI 171817

Zika virus is transmitted through Aedes mosquito bite, which can also transmit chikungunya, dengue, and yellow fever. The other modes of transmission of Zika virus is through sex and from an infected mother to the fetus. The onset of Zika virus is yet not clear. The symptoms are similar to that of dengue, including fever, skin rashes, joint pain, and headache, which are mild and last for two to seven days.

The Zika virus vaccines market is estimated to generate $14,500 million in 2017, and is expected to reach $18,697 million by 2022, growing at a CAGR of 5.2%. The market has high potential owing to increase in demand for vaccines for immunization and further prevention in regions such as Latin America and Central America. According to WHO, approximately 1.6 million individuals are infected with Zika virus, and the number is exponentially increasing. In addition, surgical demand for vaccines that can cure Zika-linked birth defects has increased.

Zika virus disease is caused by mosquitoes that belongs to Flavivirus genus, and was first identified in Uganda in 1947 in monkeys. It was later identified in humans in 1952 in Uganda and the United Republic of Tanzania. Major outbreak of the disease was reported in 2007 in the Yap Island. In addition, an association between Zika virus infection and Guillain-Barre syndrome was reported in July 2015 in Brazil, and later in October 2015, Brazil reported an association between Zika virus infection and microcephaly.

The global Zika virus vaccine market is segmented based on forecast scenario analysis and geography. On the basis of forecast scenario analysis, the market is categorized into rapid growth, moderate growth, and low growth. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS:

  • In-depth study of the global Zika virus vaccines market was conducted based on the current disease prevalence, target population, and pricing to generate market size & forecast from 2017 to 2022.
  • Potential analysis of opportunities was evaluated to understand different aspects of Zika virus vaccines that are currently clinical trials along with the variants that are expected to gain prominence in the future.
  • Key market players are profiled and their strategies are analyzed thoroughly to understand the various technologies adopted by them to manufacture Zika virus vaccines.

KEY MARKET SEGMENT:

By Forecast Scenario Analysis

  • Rapid Growth Scenario
  • Moderate Growth Scenario
  • Low Growth Scenario

By Region

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

By Country

  • Brazil
  • Mexico
  • Philippines
  • Vietnam
  • Thailand
  • Rest of the World

KEY PLAYERS

  • Immunovaccine Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Bharat Biotech International Ltd.
  • NewLink Genetics Co.
  • Inovio Pharmaceuticals, Inc.
  • GeneOne Life Science Inc.
  • GlaxoSmithKline Plc.
  • Sanofi S.A.
  • Hawaii Biotech Inc.

Table of Contents

Chapter: 1 INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. KEY BENEFITS
  • 1.3. KEY MARKET SEGMENT
  • 1.4. RESEARCH METHODOLOGY
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools and models
    • 1.4.4. Assumptions for growth scenarios
    • 1.4.5. Expected pricing per dose for Zika virus vaccine

Chapter: 2 EXECUTIVE SUMMARY

  • 2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

  • 3.1. MARKET DEFINITION AND SCOPE
  • 3.2. TOP INVESTMENT POCKETS
  • 3.3. ZIKA VIRUS-KEY FACTS
    • 3.3.1. Mode of infection and transmission of Zika virus
      • 3.3.1.1. From infected mother to child
      • 3.3.1.2. Through sex
      • 3.3.1.3. Through blood transfusion
      • 3.3.1.4. Through laboratory and healthcare setting exposure
    • 3.3.2. Signs and symptoms of infection
    • 3.3.3. Prevention and control of Zika virus
      • 3.3.3.1. Vector control options
      • 3.3.3.1.1. Targeted residual spraying
      • 3.3.3.1.2. Space spraying
      • 3.3.3.2. Personal protection measures
    • 3.3.4. Prevalence and incidence
    • 3.3.5. Diagnosis and treatment of Zika virus
      • 3.3.5.1. Trioplex real-time RT-PCR assay
      • 3.3.5.2. Zika MAC-ELISA
  • 3.4. REGULATION OF VACCINES BY FDA
    • 3.4.1. Licensure of vaccines in U.S.
    • 3.4.2. Priority Review Voucher System
    • 3.4.3. U.S. licensed flavivirus vaccines
  • 3.5. CLINICAL TRIALS
  • 3.6. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
  • 3.7. MARKET OPPORTUNITIES
    • 3.7.1. Surging need for medical solutions for the prevention & treatment of Zika-linked birth defects
    • 3.7.2. High rate of incidence of active Zika virus infection

Chapter: 4 FORECAST SCENARIO ANALYSIS OF ZIKA VIRUS VACCINES

  • 4.1. OVERVIEW
    • 4.1.1. Market size and forecast
      • 4.1.1.1. Rapid growth scenario
      • 4.1.1.2. Moderate growth scenario
      • 4.1.1.3. Low growth scenario

Chapter: 5 POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINE MARKET, BY GEOGRAPHY

  • 5.1. INTRODUCTION
  • 5.2. NORTH AMERICA
    • 5.2.1. Market size and forecast
  • 5.3. EUROPE
    • 5.3.1. Market size and forecast
  • 5.4. ASIA-PACIFIC
    • 5.4.1. Market size and forecast
  • 5.5. LAMEA
    • 5.5.1. Market size and forecast

Chapter: 6 POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES-BY COUNTRY

  • 6.1. BRAZIL
    • 6.1.1. Market size and forecast
  • 6.2. MEXICO
    • 6.2.1. Market size and forecast
  • 6.3. PHILIPPINES
    • 6.3.1. Market size and forecast
  • 6.4. VIETNAM
    • 6.4.1. Market size and forecast
  • 6.5. THAILAND
    • 6.5.1. Market size and forecast
  • 6.6. REST OF THE WORLD
    • 6.6.1. Market size and forecast

Chapter: 7 COMPANY PROFILES

  • 7.1. BHARAT BIOTECH INTERNATIONAL LTD
    • 7.1.1. Company overview
    • 7.1.2. Company Snapshot
    • 7.1.3. Operating business segments
    • 7.1.4. Product pipeline
    • 7.1.5. Research funding
    • 7.1.6. Key strategic developments
  • 7.2. GENEONE LIFE SCIENCE, INC.
    • 7.2.1. Company overview
    • 7.2.2. Company Snapshot
    • 7.2.3. Operating business segments
    • 7.2.4. Product pipeline
    • 7.2.5. Key strategic developments
  • 7.3. GLAXOSMITHKLINE PLC
    • 7.3.1. Company overview
    • 7.3.2. Company Snapshot
    • 7.3.3. Operating business segments
    • 7.3.4. Business performance
    • 7.3.5. Key strategic developments
  • 7.4. HAWAII BIOTECH INC
    • 7.4.1. Company overview
    • 7.4.2. Key strategic developments
    • 7.4.3. Company Snapshot
    • 7.4.4. Operating business segments
  • 7.5. IMMUNOVACCINE INC.
    • 7.5.1. Company overview
    • 7.5.2. Company Snapshot
    • 7.5.3. Operating business segments
    • 7.5.4. Business performance
    • 7.5.5. Product pipeline
    • 7.5.6. Key strategic developments
  • 7.6. INOVIO PHARMACEUTICALS, INC
    • 7.6.1. Company overview
    • 7.6.2. Company Snapshot
    • 7.6.3. Operating business segments
    • 7.6.4. Business performance
    • 7.6.5. Product pipeline
    • 7.6.6. Research funding
    • 7.6.7. Key strategic developments
  • 7.7. NEWLINK GENETICS CORPORATION
    • 7.7.1. Company overview
    • 7.7.2. Company Snapshot
    • 7.7.3. Business performance
    • 7.7.4. Product pipeline
  • 7.8. SANOFI S.A.
    • 7.8.1. Company overview
    • 7.8.2. Company Snapshot
    • 7.8.3. Operating business segments
    • 7.8.4. Business performance
    • 7.8.5. Product pipeline
    • 7.8.6. Research funding
    • 7.8.7. Key strategic developments
  • 7.9. TAKEDA PHARMACEUTICAL CO., LTD.
    • 7.9.1. Company overview
    • 7.9.2. Company Snapshot
    • 7.9.3. Operating business segments
    • 7.9.4. Business performance
    • 7.9.5. Product pipeline
    • 7.9.6. Research funding

List of Tables

  • TABLE 1. RAPID GROWTH SCENARIO OF POTENTIAL ZIKA VIRUS VACCINES MARKET, BY GEOGRAPHY, 2017-2022 ($MILLION)
  • TABLE 2. MODERATE GROWTH SCENARIO OF POTENTIAL ZIKA VIRUS VACCINES MARKET, BY GEOGRAPHY, 2017-2022 ($MILLION)
  • TABLE 3. LOW GROWTH SCENARIO OF POTENTIAL ZIKA VIRUS VACCINES MARKET, BY GEOGRAPHY, 2017-2022 ($MILLION)
  • TABLE 4. NORTH AMERICA: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 5. EUROPE: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 6. ASIA-PACIFIC: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 7. LAMEA: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 8. BRAZIL: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 9. MEXICO: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 10. PHILIPPINES: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 11. VIETNAM: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 12. THAILAND: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 13. REST OF THE WORLD: POTENTIAL ANALYSIS OF ZIKA VIRUS VACCINES MARKET, ($MILLION), 2017-2022
  • TABLE 14. BHARAT BIOTECH INTERNATIONAL LIMITED: COMPANY SNAPSHOT
  • TABLE 15. BHARAT BIOTECH INTERNATIONAL LIMITED: OPERATING SEGMENTS
  • TABLE 16. GENEONE LIFE SCIENCE INC.: COMPANY SNAPSHOT
  • TABLE 17. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 18. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 19. HAWAII BIOTECH INC.: COMPANY SNAPSHOT
  • TABLE 20. HAWAII BIOTECH INC.: OPERATING SEGMENTS
  • TABLE 21. IMMUNOVACCINE INC.: COMPANY SNAPSHOT
  • TABLE 22. INOVIO PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 23. NEWLINK GENETICS: COMPANY SNAPSHOT
  • TABLE 24. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 25. SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 26. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 27. TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS

List of Figures

  • FIGURE 1. ZIKA VIRUS VACCINES MARKET SEGMENTATION
  • FIGURE 2. NUMBER OF COUNTRIES AND TERRITORIES REPORTING MOSQUITO-BORNE ZIKA VIRUS TRANSMISSION AS OF OCTOBER 27, 2016, BY REGION
  • FIGURE 3. RISK OF ZIKA VIRUS INFECTION DUE TO TRAVELERS FROM BRAZIL TO SPECIFIC COUNTRIES
  • FIGURE 4. FLOWCHART OF VACCINE APPROVAL
  • FIGURE 5. NUMBER OF ZIKA VIRUS INFECTION CASES IN LATIN AMERICA BY COUNTRY
  • FIGURE 6. NUMBER OF COUNTRIES & TERRITORIES REPORTING MOSQUITO-BORNE ZIKA VIRUS INFECTION BY REGION
  • FIGURE 7. TIMELINE OF SPREAD FOR ZIKA VIRUS
  • FIGURE 8. NUMBER OF LABORATORY-CONFIRMED ZIKA VIRUS INFECTION CASES IN U.S., AS OF NOVEMBER 2016
  • FIGURE 9. REPORTED TRAVEL-ASSOCIATED CASES OF ZIKA VIRUS IN BRITISH POPULATION, BY COUNTRY
  • FIGURE 10. GLAXOSMITHKLINE PLC.: REVENUE ($MILLION), 2013-2015
  • FIGURE 11. GLAXOSMITHKLINE PLC.: BY PRINCIPLE PRODUCT CATEGORY, 2015%
  • FIGURE 12. GSK: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIGURE 13. IMMUNOVACCINE INC.: REVENUE ($MILLION), 2013-2015
  • FIGURE 14. INOVIO PHARMACEUTICALS, INC.: REVENUE ($MILLION), 2013-2015
  • FIGURE 15. NEWLINK GENETICS: REVENUE ($MILLION), 2013-2015 85
  • FIGURE 16. SANOFI S.A.: REVENUE ($MILLION), 2013-2015
  • FIGURE 17. SANOFI S.A.: BY PRINCIPLE PRODUCT CATEGORY, 2015%
  • FIGURE 18. SANOFI S.A.: REVENUE, BY GEOGRAPHY, 2015 (%)
  • FIGURE 19. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE ($MILLION), 2013-2015
Back to Top